- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£954GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£954GBP
- Report
- March 2025
- 450 Pages
Global
From €4478EUR$5,000USD£3,818GBP
- Report
- February 2025
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- February 2025
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- February 2025
- 182 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- January 2025
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- January 2025
- 180 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- August 2024
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- April 2025
Global
From €2642EUR$2,950USD£2,252GBP
- Report
- November 2024
- 301 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- February 2022
- 84 Pages
Global
From €1164EUR$1,299USD£992GBP
- Report
- June 2025
Global
From €400EUR$478USD£353GBP
- Report
- November 2022
- 154 Pages
Global
From €4478EUR$5,000USD£3,818GBP
- Report
- June 2022
- 1500 Pages
Global
From €3493EUR$3,900USD£2,978GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €8061EUR$9,000USD£6,872GBP
- Report
- November 2021
- 222 Pages
Global
From €2687EUR$3,000USD£2,291GBP
- Report
- March 2021
- 240 Pages
United States
From €2687EUR$3,000USD£2,291GBP
- Report
- May 2024
- 420 Pages
Global
From €2687EUR$3,000USD£2,291GBP
- Report
- February 2022
- 360 Pages
United States
From €3224EUR$3,600USD£2,749GBP

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more